Pegylated liposomal doxorubicin for myeloid neoplasms

Pegylated liposomal doxorubicin (Peg-Dox) treatment resulted in a good outcome for patients with lymphoma and multiple myeloma, with reduced cardiotoxicity and an improved pharmacokinetic profile when compared to those of conventional doxorubicin. However, the use of Peg-Dox in myeloid neoplasms rem...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Cheng, Yao, Han, Kong, Pei-Yang, Liu, Yao, Gao, Lei, Gao, Li, Ma, Ying-Ying, Liu, Jun, Tan, Xu, Zhang, Xi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Clinical Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6749968/
https://www.ncbi.nlm.nih.gov/pubmed/31283544
http://dx.doi.org/10.1097/CAD.0000000000000811

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6749968/
https://www.ncbi.nlm.nih.gov/pubmed/31283544
http://dx.doi.org/10.1097/CAD.0000000000000811

Ejemplares similares